switching between glp-1 agonists 📚There’s a growing trend you’re seeing for a reason: some patients are from medications to dual agonists., This isn’t about hype. It’s about physiology., 🧠 GLP-1 like Semaglutide #4 NN Clinical Use

Deletion of GIP receptor has been found to counteract high-fat diet induced weight gain in mice, suggesting a causal role of GIP in development of obesity [36]

Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology

[28] Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T.,

The PREDIMED data is instructive: participants consuming substantial amounts of EVOO in an unrestricted-calorie context did not gain weight -- and showed slight improvements in central adiposity -- over nearly five years

[5] Unknown Long-Term Consequences The most significant concern is that Ozempic overall is still a relatively new drug, particularly in the context of long-term, non-diabetic use for weight management